Quarterly results · VISTAPH
VISTA PHARMACEUTICALS LTD. reported revenue of ₹0 cr and net profit of -₹5.86 cr in Q4 FY26 (quarter ended 31 Mar 2026), -292.0% year on year. Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated automatically from exchange filings.
| Quarter | Q4 FY26 |
|---|---|
| Quarter ended | 31 Mar 2026 |
| Revenue | ₹0 cr |
| Revenue YoY | -100.0% |
| Operating profit | -₹7.25 cr |
| Operating margin | — |
| Net profit | -₹5.86 cr |
| Net profit YoY | -292.0% |
| Net profit QoQ | -152.8% |
| Net margin | — |
| Basic EPS | ₹-0.91 |
| TTM revenue | ₹5.4 cr |
| TTM net profit | -₹12.06 cr |
| TTM net margin | -223.4% |
VISTA PHARMACEUTICALS LTD. (VISTAPH) has reported its Q4 FY26 results for the quarter ended 2026-03-31. The company posted revenue of ₹0 cr and a net profit of -₹5.86 cr, translating into earnings per share of ₹-0.91.
Compared with the same quarter a year earlier, revenue declined sharply by -100.0% and net profit declined sharply by -292.0%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Revenue
₹0 cr
-100.0% YoY
Net profit
-₹5.86 cr
-292.0% YoY
Operating profit
-₹7.25 cr
-561.2% YoY
EPS
₹-0.91
— YoY
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q4 FY262026-03-31 | ₹0 cr | -₹7.25 cr | -₹5.86 cr | — | — | ₹-0.91 | -292.0% | -152.8% |
| Q3 FY262025-12-31 | ₹2.42 cr | -₹3.19 cr | -₹2.32 cr | -132.0% | -95.9% | ₹-0.41 | — | +10.4% |
| Q2 FY262025-09-30 | ₹1.46 cr | -₹3.64 cr | -₹2.59 cr | -248.7% | -177.0% | ₹-0.42 | — | -100.6% |
| Q1 FY262025-06-30 | ₹1.52 cr | -₹1.29 cr | -₹1.29 cr | -84.7% | -85.0% | ₹-0.22 | — | +13.7% |
| Q4 FY252025-03-31 | ₹3.23 cr | -₹1.1 cr | -₹1.5 cr | -33.9% | -46.3% | — | — | — |
| TTM (last 4 quarters) | ₹5.4 cr | -₹15.37 cr | -₹12.06 cr | -284.6% | -223.4% | ₹-1.96 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|---|---|---|---|---|
| Revenue / Sales | ₹0 cr | ₹2.42 cr | ₹1.46 cr | ₹1.52 cr | ₹3.23 cr |
| Total expenses | ₹7.25 cr | ₹5.61 cr | ₹5.1 cr | ₹2.81 cr | ₹4.33 cr |
| Gross profit | ₹0 cr | ₹0.16 cr | -₹0 cr | ₹0.02 cr | ₹0.54 cr |
| Operating profit (EBIT) | -₹7.25 cr | -₹3.19 cr | -₹3.64 cr | -₹1.29 cr | -₹1.1 cr |
| Operating margin | — | -132.0% | -248.7% | -84.7% | -33.9% |
| Interest cost | ₹0.55 cr | ₹0.18 cr | ₹0.18 cr | ₹0.19 cr | ₹0.21 cr |
| Profit before tax | -₹7.77 cr | -₹3.28 cr | -₹3.62 cr | -₹1.48 cr | -₹1.06 cr |
| Tax expense | -₹1.91 cr | -₹0.96 cr | -₹1.03 cr | -₹0.19 cr | ₹0.43 cr |
| Effective tax rate | 24.5% | 29.3% | 28.5% | 12.8% | -40.8% |
| Net profit (PAT) | -₹5.86 cr | -₹2.32 cr | -₹2.59 cr | -₹1.29 cr | -₹1.5 cr |
| Net profit margin | — | -95.9% | -177.0% | -85.0% | -46.3% |
| Basic EPS | ₹-0.91 | ₹-0.41 | ₹-0.42 | ₹-0.22 | — |
| Diluted EPS | ₹-0.91 | ₹-0.41 | ₹-0.44 | ₹-0.22 | — |
| Growth | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|---|---|
| Revenue YoY | -100.0% | — | — | — | — |
| Revenue QoQ | -100.0% | +65.3% | -3.7% | -53.0% | — |
| Operating profit YoY | -561.2% | — | — | — | — |
| Operating profit QoQ | -127.0% | +12.2% | -182.6% | -17.4% | — |
| Net profit YoY | -292.0% | — | — | — | — |
| Net profit QoQ | -152.8% | +10.4% | -100.6% | +13.7% | — |
| EPS YoY | — | — | — | — | — |
| EPS QoQ | -122.0% | +2.4% | -90.9% | — | — |
Full-year performance for VISTA PHARMACEUTICALS LTD., useful for reading each quarter in context.
| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹5.4 cr | ₹10.07 cr | ₹10.29 cr | ₹1 cr |
| Total expenses | ₹20.76 cr | ₹14.84 cr | ₹14.19 cr | ₹4.89 cr |
| Gross profit | ₹0.18 cr | ₹1.73 cr | ₹1.15 cr | -₹1.96 cr |
| Operating profit (EBIT) | -₹15.37 cr | -₹4.77 cr | -₹3.9 cr | -₹3.88 cr |
| Operating margin | -284.6% | -47.3% | -37.9% | -386.8% |
| Interest cost | ₹1.1 cr | ₹0.96 cr | ₹1.24 cr | ₹1.31 cr |
| Profit before tax | -₹16.15 cr | -₹5.29 cr | -₹5.18 cr | -₹5.88 cr |
| Tax expense | -₹4.09 cr | -₹0.64 cr | -₹0.67 cr | -₹0.21 cr |
| Effective tax rate | 25.3% | 12.1% | 12.9% | 3.6% |
| Net profit (PAT) | -₹12.06 cr | -₹4.65 cr | -₹4.51 cr | -₹5.66 cr |
| Net profit margin | -223.4% | -46.1% | -43.9% | -564.1% |
| Basic EPS | ₹-1.96 | ₹-0.79 | ₹-1.03 | ₹-1.54 |
| Diluted EPS | ₹-1.96 | ₹-0.79 | ₹-1.03 | ₹-1.54 |
Topline for Q4 FY26 came in at ₹0 cr against ₹3.23 cr in Q4 FY25, and ₹2.42 cr in the preceding Q3 FY26 quarter.
On a sequential basis revenue declined -100.0%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹7.25 cr, with operating profit declined -561.2% year on year.
Net profit of -₹5.86 cr works out to a net margin of not available compared with -46.3% in the year-ago quarter.
Below the operating line, VISTA PHARMACEUTICALS LTD. reported profit before tax of -₹7.77 cr, a tax charge of -₹1.91 cr (effective rate 24.5%), interest cost of ₹0.55 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from -₹2.32 cr in Q3 FY26 to -₹5.86 cr in Q4 FY26, a change of -152.8%.
Across the trailing four quarters VISTA PHARMACEUTICALS LTD. has generated revenue of ₹5.4 cr and net profit of -₹12.06 cr, a trailing net margin of -223.4%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹5.4 cr with net profit of -₹12.06 cr and EPS of ₹-1.96, versus the prior year where revenue declined -46.4% and profit declined -159.5%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
VISTA PHARMACEUTICALS LTD. has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
No results report published for VISTAPH yet — our desk covers each quarter within minutes of the filing.
In Q4 FY26 (quarter ended 31 Mar 2026), VISTA PHARMACEUTICALS LTD. reported revenue of ₹0 cr and net profit of -₹5.86 cr, a change of -292.0% year on year on -100.0% revenue growth. EPS stood at ₹-0.91.
VISTA PHARMACEUTICALS LTD. posted a net profit margin of not available and an operating margin of not available in Q4 FY26. On a trailing twelve-month basis, revenue is ₹5.4 cr and net profit -₹12.06 cr.
VISTA PHARMACEUTICALS LTD. net profit changed -152.8% quarter on quarter, from -₹2.32 cr in Q3 FY26 to -₹5.86 cr in Q4 FY26.
VISTA PHARMACEUTICALS LTD. has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Results coverage for VISTAPH will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the VISTAPH stock page.
For FY26, VISTA PHARMACEUTICALS LTD. reported full-year revenue of ₹5.4 cr and net profit of -₹12.06 cr, with EPS of ₹-1.96.
Past results dates for VISTAPH will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
